Several small- and mid-cap biotech stocks surged on Friday as investors focused on company-specific clinical timelines, development updates and, in one case, ongoing corporate strategy. TherapeuticsMD climbed more than 20%, while Sensei Biotherapeutics and Alumis also posted double-digit gains tied to upcoming clinical readouts and regulatory milestones.
Key takeaways
- Price moves: TherapeuticsMD rose more than 20%, Sensei Biotherapeutics gained about 20%, and Alumis added roughly 16% on Friday.
- Key catalyst: Investors rewarded a mix of strategic review efforts, clinical trial enrollment and expected topline timing, and preparation for an NDA submission.
- What it implies: The market is continuing to price near-term probability around catalysts scheduled across 2026 and 2027, with risk concentrated around clinical and regulatory execution.
- One standout: Shattuck Labs jumped without a specific announced headline, suggesting traders were leaning on recent clinical momentum.
Strategic review sparks momentum in TherapeuticsMD
TherapeuticsMD, which owns rights to pharmaceutical royalties, was among the day’s top gainers after the company said it continues to evaluate a range of strategic alternatives. Shares rose more than 20%, reflecting investor interest in the possibility of transactions that could unlock value from its royalty portfolio.
TherapeuticsMD said its options include acquisitions, mergers, asset sales, business combinations and other potential transactions. The latest financial update cited in the company’s filing for the first quarter ended March 31, 2026, showed net income from continuing operations of $103 thousand, alongside license revenue of $724 thousand. That compares with a net loss of $636 thousand and license revenue of $393 thousand in the first quarter of 2025.
The company closed Friday’s trading at $2.20, up 20.88%.
Clinical timelines drive gains for Sensei Biotherapeutics and Alumis
Sensei Biotherapeutics rallied sharply as investors looked ahead to multiple clinical milestones tied to its platform. The company’s PIKTOR program—acquired through Sensei’s February acquisition of Faeth Therapeutics—remains central to the near-term narrative.
According to the company’s development plans, PIKTOR entered Phase 1b/2 dosing after the first patient was treated in April 2026 for HR+/HER2- advanced breast cancer. Interim data are expected in 2027. In endometrial cancer, PIKTOR is in Phase 2 development, with topline data on track for the second half of 2026. Sensei’s stock closed at $13, up 20.48%.
Alumis, another late-stage name in immunology, also climbed on Friday as its regulatory and trial schedule came into focus. The company is progressing Envudeucitinib (formerly ESK-001) for systemic immune-mediated disorders, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus.
For plaque psoriasis, Alumis said it is on track to submit an NDA for Envudeucitinib in the fourth quarter of 2026. For systemic lupus erythematosus, the program is in a potentially pivotal Phase 2b study, with topline data expected next quarter, referenced as Q3 2026. Shares finished the session at $24.15, up 15.55%.
Other biotech movers: Shattuck, Enliven and Aktis Oncology
Shattuck Labs surged more than 18% even without a specific new announcement driving the move, according to the market recap. The clinical-stage biotechnology firm is developing DR3 blocking antibodies, including SL-325, which targets inflammatory and immune-mediated diseases such as Crohn’s disease and ulcerative colitis.
Shattuck recently reported results from a Phase 1 first-in-human study evaluating SL-325 in healthy participants. The company said the candidate was safe and well tolerated across a wide dosing range. Based on those results, it expects to initiate a Phase 2 clinical trial of SL-325 in Crohn’s disease in the third quarter of 2026. The stock closed at $4.94, up 18.18%.
Enliven Therapeutics added about 14% after reporting updated positive data from its Phase 1 ENABLE trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia. According to the company, the study showed meaningful responses across lines of therapy in heavily pretreated patients, including responses among patients who had previously not responded to the most effective approved therapies. The company also reiterated that ELVN-001 displayed a favorable safety and tolerability profile, supported by its selectivity. Enliven said it expects to start the ENABLE-2 Phase 3 trial in 2L+ CML in the second half of 2026. Shares closed at $46.13, up 14.30%.
Aktis Oncology also rose after investors weighed program progress and company-specific timing. The stock closed at $21.93, up 12.69%. Aktis made its Nasdaq debut under the ticker AKTS on January 9, 2026, at a public offering price of $18, and the lockup period is set to expire on July 8, 2026.
In terms of pipeline, Aktis said last month it shared first clinical imaging and dosimetry data for AKY-2519, a candidate designed for tumors expressing B7-H3, including metastatic castration-resistant prostate cancer, lung cancer and colorectal cancer. The company is enrolling in an mCRPC-dedicated Phase 1b trial of AKY-2519 for PLUVICTO-naïve and PLUVICTO-experienced patients, with preliminary data expected in 2027. A second Phase 1b trial in other B7-H3-expressing solid tumors is planned for the second half of 2026. Aktis’ lead program, AKY-1189, is also in Phase 1b testing in Nectin-4 expressing tumors, with preliminary data expected in the first quarter of 2027.
Bigger picture: investors focusing on 2026–2027 catalyst density
Across the group, the common thread is timing. Several of the day’s biggest gainers pointed to planned inflection points in 2026—such as Phase 2b topline data and trial starts—and longer-dated readouts scheduled for 2027. Investors appear to be concentrating on the next set of binary outcomes, including clinical efficacy signals, safety and tolerability and regulatory sequencing.
With multiple companies setting expectations for data releases and trial milestones in the coming quarters, attention will likely return to execution risk: enrollment pace, endpoint selection and whether early-phase results translate into registration-enabling outcomes.
What to watch next: upcoming interim and topline readouts scheduled for 2026 (including Sensei’s second-half 2026 endometrial cancer topline and Alumis’ Q3 2026 lupus data), trial initiation timing for 2026 (including Shattuck’s Phase 2 start in Q3) and the broader market’s willingness to price in clinical probability ahead of key Phase 2 and Phase 3 catalysts through 2027.
